MarketPulse

obesity treatment

13 articles
BenzingaBenzinga··Vandana Singh

Novo Nordisk Wins FDA Nod for High-Dose Wegovy, Expanding GLP-1 Arsenal

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.
NVOHIMSFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Structure Therapeutics Inc.

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.
GPCRPhase 2 clinical trialFDA approval
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

GLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk Stock Looks Cheap, But Execution Risks Cloud Recovery Outlook

Novo Nordisk stock trades cheap but faces execution headwinds versus Eli Lilly's superior operational performance in the booming GLP-1 market.
LLYNVOweight loss drugspharmaceutical competition
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.
LLYSNYNVOAZNIVBIYclinical trialsmarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Aligos Therapeutics, Inc.

Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline

Aligos reports $24.2M net loss in 2025, down 82% YoY. Key hepatitis B study enrollment complete; cash runway extends to Q3 2026.
ALGSPhase 2 clinical trialfinancial results
BenzingaBenzinga··Vandana Singh

Novo Nordisk Cuts GLP-1 Drug Prices 50% Amid Clinical Setbacks

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.
LLYNVOclinical trialprice reduction
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Novo Nordisk Licenses Vivtex Technology for Oral Obesity and Diabetes Treatments

Novo Nordisk licenses Vivtex's oral drug-delivery technology for obesity and diabetes treatments, with potential $2.1B in milestone payments to develop oral alternatives to injectable biologics.
NVOpartnershipobesity treatment
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk's GLP-1 Dominance May Not Deliver Mega Returns

Novo Nordisk dominates the GLP-1 market with Ozempic and Wegovy, but faces stiff competition from Eli Lilly and disappointing trial results that may limit exceptional long-term returns.
LLYNVOdividend stockslong-term investing
Investing.comInvesting.com··Itai Smidt

Novo Nordisk Reassesses Growth Outlook Following CagriSema Trial Setback

Novo Nordisk stock drops 15.9% after CagriSema obesity drug fails trial versus competitor tirzepatide, signaling intensifying competition in the GLP-1 market despite Wegovy's strength.
LLYNVOGLP-1 drugsWegovy
The Motley FoolThe Motley Fool··Rich Smith

Novo Nordisk Stock Pullback Creates Entry Point for Long-Term GLP-1 Investors

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.
LLYNVOstock valuationdividend stocks
BenzingaBenzinga··Prnewswire

Digital Health Expansion Accelerates as Market Reaches $6 Trillion Milestone

Global health market reaches $6 trillion milestone by 2026, driven by consumer demand for wellness products. Companies expand through innovation in digital health, pharmaceuticals, and specialized care solutions.
VKTXAMRXPBHPODDobesity treatmenthealth and wellness market
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition